Skip to content

The impact of preemptive FDI on multilevel lumbar fusion for the elderly: a prospective, multicenter, randomized trial (the PFIMLE trial)

The impact of preemptive FDI on multilevel lumbar fusion for the elderly: a prospective, multicenter, randomized trial (the PFIMLE trial)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099482
Enrollment
Unknown
Registered
2025-03-25
Start date
2024-11-13
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic spinal degeneration

Interventions

FDI group:Patients in the isomaltose iron group received intravenous infusion of isomaltose iron one day before surgery, with the dosage based on weight assessment (500mg for body weight= 70kg). The s
CON group:Some amount of normal saline on one day before surgery.

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: (1) Age >= 60 years old; (2) Perform multi segment (>= 2 segments) spinal fusion surgery; (3) The patient signs an informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) Iron overload or iron utilization disorders (such as hemochromatosis, hemochromatosis containing iron); (2) There are various types of anemia at baseline (Hb3 times the upper limit of normal]; (5) Acute or chronic infectious diseases; (6) Patients with immune or inflammatory diseases (such as systemic lupus erythematosus, rheumatoid arthritis); (7) Hypersensitivity reactions occur to active ingredients, isomaltulose iron injection, and any excipients; (8) Known to have experienced severe hypersensitivity reactions to other parenteral iron agents; (9) Used iron therapy within 3 months before surgery; (10) Three months prior to surgery, red blood cell stimulating agents were used; (11) History of blood transfusion within one month prior to surgery.

Design outcomes

Primary

MeasureTime frame
Hemoglobin levels at 4 weeks postoperatively;

Secondary

MeasureTime frame
Hemoglobin levels at baseline, postoperative 1 day, 3 days, and 1 week;The incidence of anemia at discharge and 4 weeks after surgery (anemia definition: male hemoglobin<13g/dL, female hemoglobin<12g/dL);Baseline, postoperative 1 day, 3 days, 1 week, and 4 weeks iron metabolism indicators (iron, ferritin, and transferrin saturation);Allogeneic transfusion rate and mean amount of allogeneic transfusion (unit IU);Length of postoperative stay;Postoperative drainage time, daily drainage volume, and total drainage volume;At baseline and four weeks after surgery, patient satisfaction was assessed using the Likert scale, and quality of life was evaluated using the Five Dimensional Health Scale (EQ-5D);

Countries

China

Contacts

Public ContactHaolin Sun

Peking University First Hospital

lichunde@vip.sina.com+86 155 1023 0368

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026